Literature DB >> 10052903

Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital.

J H Sloos1, J A van de Klundert, L Dijkshoorn, C P van Boven.   

Abstract

The susceptibility of two collections of coagulase-negative staphylococci (CNS) isolated from clinical specimens for teicoplanin and vancomycin were compared. They comprised 91 and 101 isolates, collected in 1985 and 1994 respectively, from different departments of a teaching hospital. MICs of vancomycin and teicoplanin were determined by a modified Etest method. Additionally, a disc diffusion test was performed for teicoplanin. All isolates were susceptible to vancomycin (MIC < or = 4 mg/L). Two of the 91 isolates collected in 1985 were intermediate to teicoplanin (MIC between 8 and 32 mg/L), whereas in 1994 the number of intermediate isolates was 20 out of 101 (P < 0.01). The correlation between MICs, as determined by the modified Etest assay, and disc diffusion zones was poor (r = -0.35). Results show that resistance to teicoplanin in CNS has increased in the study hospital over a period of 9 years. This increase is likely to be correlated with the introduction of teicoplanin. Furthermore, a disc diffusion method does not appear to be the first method of choice for detection of strains of CNS with diminished susceptibility to teicoplanin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052903     DOI: 10.1093/jac/42.6.787

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci.

Authors:  M Bertin; A Muller; X Bertrand; C Cornette; M Thouverez; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece.

Authors:  Athanassios Tsakris; Ekaterini Papadimitriou; John Douboyas; Fotini Stylianopoulou; Evangelos Manolis
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.